RLAY Stock Recent News
RLAY LATEST HEADLINES
Relay Therapeutics completed what was at the time the 3rd largest Biotech IPO in history in 2020, raising $400m. The company promised to use cutting edge AI driven technology to identify and develop drug targets with a primary focus on precision oncology.
Relay Therapeutics Inc (NASDAQ: RLAY) shares are trading lower by 11.33% to $25.54 Tuesday morning after the company priced a roughly 11.32 million share public offering of common stock at $26.50 per share.
The stock price of Relay Therapeutics (RLAY) fell by 0.72% today. This is why.
Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T. Relay Therapeutics to host a conference call on September 12th at 8:00 am E.T.
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report second quarter 2022 financial results and corporate highlights after the close of market on Thursday, August 4, 2022. The company will not be conducting a teleconference in conjunction with its financial results press release.
CAMBRIDGE, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced registration is open for the virtual analyst and investor event on June 27, 2022 from 8:00 a.m. to 9:00 a.m. ET.
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the Cowen 3rd Annual Oncology Innovation Summit on Thursday, June 2, 2022, at 11:30 a.m. ET and at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at 5:40 p.m. ET.